The effect of sitagliptin on insulin secretion in Japanese type 2 diabetic patients.
- Conditions
- Japanese type 2 diabetes
- Registration Number
- JPRN-UMIN000004791
- Lead Sponsor
- Department of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
1.Patients who could not sign informed consent for this study. 2.Patients with history of malignancy. 3.Patients with severe complications as follows: dysfunction of heart, lung, liver, kidney and pancreas and cerebral vessel disease as well as infections. 4.Patients with severe diabetic complications, such as bleeding diabetic retinopathy, diabetic nephropathy (eGFR<30), diabetic neuropathy, gangrene, ketosis, diabetic pre-coma and diabetic coma. 5.Patients during pregnancy or possible pregnant women. 6.Patients with type 2 diabetes using other antidiabetic drugs. 7.Patients with gastrointestinal symptoms such as diarrhea and vomiting. 8.Patients who are inadequate to entry this study. 9.Patients with severe frequent hypoglycemia and condition of hypoglycemia-unconsciousness. 10.Patients who are treated or will be treated with drugs which increase blood glucose such as steroids, interferon and tacrolimus.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method insulinogenic index
- Secondary Outcome Measures
Name Time Method 1.HbA1c (%) (JDS value) 2.GA (%) 3.CPR/PG during OGTT 4.insulin/pro insulin rate 5.ISI composite=10000/(FPGxFIRIxmean OGTT PGxmean OGTT IRI)0.5 6.total GIP, total GLP-1 (pg/ml) 7.high-sensitive C-reactive protein (mg/) 8.total-Cho, LDL-Cho, HDL-Cho (mg/dl) 9.urinary albumin/creatinin (mg/g.Cr) 10.blood pressure (mmHg) 11.body weight (Kg)